The ultra scale-down (USD) approach pioneered by the department aims to reproduce full-scale manufacturing in research labs. Ultra scale-down technologies are combination of proprietary ultra scale-down devices and laboratory methodologies. They have the potential to transform and accelerate bioprocess development, enabling the design of robust manufacturing for the biotech industries to produce biopharmaceuticals, cell and gene therapies, vaccines, enzymes and other biochemicals as building blocks for food, energy, and other products.
kompAsTM is an example of academic innovation going mainstream via commercialisation. The name is inspired by the word:“compass”, a tool that enables explorers to navigate their journeys. KompAsTM is therefore a reference to its role in bioprocess development as it enables the prediction of optimal bioprocess routes during development at laboratory scale.
Dr Nick Everdell, head of Gowerlabs speaks about this new partnership: “Gowerlabs are very proud to be part of this new venture, collaborating closely with the Biochemical Engineering Department at UCL. We are excited to be expanding our product portfolio and diversifying into a new area of healthcare engineering.”
Some of the researchers involved in the development and application of ultra scale-down talk about the launch of kompAsTMas a commercial product in this video:
If you would like to know more about kompAsTM or to pre-order via our licensed partner please contact: usdtechnologies@ucl.ac.uk
